Takeda Pharmaceutical (TAK) Enterprise Value (2017 - 2026)

Takeda Pharmaceutical's Enterprise Value history runs 10 years deep, the most recent figure standing at -$4.1 billion for Q1 2026.

• On a quarterly basis, Enterprise Value fell 52.82% year-over-year to -$4.1 billion in Q1 2026; TTM through Mar 2026 was -$4.1 billion, a 52.82% decrease from a year earlier, with the FY2026 full-year figure at -$4.2 billion, down 58.96% from the prior year.
• Enterprise Value grew to -$4.1 billion in Q1 2026 per TAK's latest filing, from -$7.0 billion in the prior quarter.
• Across five years, Enterprise Value topped out at -$2.7 billion in Q1 2025 and bottomed at -$8.2 billion in Q3 2022.
• The 5-year median for Enterprise Value is -$5.9 billion (2024), against an average of -$5.6 billion.
• Across the five-year window, Enterprise Value surged 46.46% in 2023 and sank 72.06% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$6.8 billion in 2022, then soared by 44.5% to -$3.8 billion in 2023, then slumped by 55.4% to -$5.9 billion in 2024, then retreated by 19.53% to -$7.0 billion in 2025, then surged by 42.12% to -$4.1 billion in 2026.
• Per Business Quant, the three latest TAK Enterprise Value figures stand at -$4.1 billion (Q1 2026), -$7.0 billion (Q4 2025), and -$7.1 billion (Q3 2025).